Business Wire

Diversified Nano Solutions Corp. and Screen Graphic Solutions Co., Ltd. Enter into a Strategic Relationship to Offer Revolutionary INKcrypt® DNA-Identity Ink and x-nano™ Special Effect Inkjet Inks for Screen Inkjet Platforms

Del

Diversified Nano Solutions Corporation (DNSC) and Screen Graphic Solutions Co, Ltd. (Screen) announce a strategic cooperation to offer revolutionary INKcrypt® anti-counterfeit solutions and x-nano™ special effect digital inkjet inks for Screen inkjet platforms. At PRINT17, Screen will demonstrate DNSC inkjet solutions (MICR and invisible UV fluorescent inks) with Truepress Jet520NX at booth 2613, September 10-14, 2017, in Chicago.

DNSC specializes in developing and manufacturing security ink, high-performance black & color ink, MICR ink, special effect inks, and associated fluids for digital printing platforms, which complements Screen’s focus on developing, manufacturing and marketing best-in-class Inkjet presses to clients worldwide.

“Our strategic cooperation with DNSC will allow Screen accelerated expansion and penetration of existing and new market opportunities for its portfolio of high performance digital inkjet platforms in particular related to graphics, security, finance (MICR), transpromo, and a fast growing demand in anti-counterfeit solutions,” said Seiichi Nakao, Global Business Director of Continuous HSI printers. “Screen’s family of Truepress Jet520 HD, ZZ, EX and NX, high speed, mono and high resolution full color inkjet presses are ideally positioned to support any market demand most competitively. In addition to conventional ink variations, we will be able to strongly promote the expansion of applications of inkjet presses.”

Bruce Carnes, Director of Business Development, added, “We are pleased with our opportunity to collaborate with Screen, a leading inkjet system manufacturer and famous brand in the industry, to jointly bring new inkjet output possibilities to users worldwide.”

Ideally suited for Screen inkjet platforms and a patent-pending industry innovation is DNSC’s revolutionary INKcrypt® technology, which integrates with inkjet and other fluid dispensing platforms. Users are now able to distinguish documents and/or products based on unique ink-identity, which can be authenticated on the spot using www.inkcryptink.com and smart devices. INKcrypt® provides item tracing, complete supply chain transparency, and elimination of fraud and counterfeiting. The INKcrypt® technology is based on unique DNA-identity markers, customized for each user, which can be added without changing the ink’s or fluid’s physical properties. INKcrypt® protects consumers and businesses from fraud, complete theft of product value, and health risks associated with counterfeiting, while brand owners prevent loss and strengthen customer confidence and loyalty.

Screen’s inkjet systems will be fully INKcrypt® compliant and support DNSC’s x-nano™ ink portfolio, including:

MICR ink (K-Ink Series), invisible UV fluorescent color, infrared-absorbing (I-Ink Series), and special inks. DNSC inks, customized for Screen systems, will be available through Screen’s sales channels worldwide. Screen and DNSC jointly are ideally positioned to help users create differentiated, high-value output through personalization using x-nano™ special effect inks such as magnetic (MICR), invisible fluorescent and security inks for digital inkjet platforms.

About Screen

SCREEN Graphic Solutions Co., Ltd. (SCREEN GA) is a core group company of SCREEN Holdings Co., Ltd. (formerly Dainippon Screen Mfg. Co., Ltd.) and is also one of the world’s leading manufacturers of graphic arts equipment. SCREEN GA has utilized the image processing and inkjet technologies developed by the SCREEN Group over many decades to create the Truepress Jet series of inkjet POD presses, which includes roll-fed, UV label, large size and sheet-fed systems. The comprehensive lineup also features market-leading products such as EQUIOS universal workflow and the PlateRite series of CtP devices.

About DNSC

Diversified Nano Solutions Corporation (DNSC), based in San Diego, California, specializes in developing and manufacturing nano materials and fluids used in high-performance functional inks for digital printing, unique customer applications, research and surface treatments. DNSC has developed an extensive product line of inks known as x-nano™, providing a range of solutions that utilize nanoparticles in long-term stable suspension, including MICR inks (Magnetic Ink Character Recognition), invisible color (RGB) fluorescent inks (UV [250-365nm] / IR [780-1050nm]), special pigmented/hybrid inks, and special pigmented/hybrid inks for food grade and non-food applications. These digital inks address drop-on-demand inkjet applications based on thermal and piezo print heads using aqueous, oil, energy curable (UV/LED) and eco-solvent-based inks. The company maintains high volume manufacturing facilities in Europe and the USA. DNSC’s inks are suitable for systems and platforms offered by various inkjet printer vendors and inkjet head manufacturers.

DNSC will be presenting INKcrypt® inks and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.

Visit booth 854 and discover DNSC digital INKS unlimited!

Contact information

Diversified Nano Solutions Corporation
Linda Meyers
US Headquarters: +1.858.924.1005
EMEA: +41.41 874 08 50
info@diversifiednano.com
www.diversifiednano.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31Pressemelding

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom